Mitsubishi Tanabe Pursues Next Generation Vaccines With Medicago, Tag-teams DPP-4 Market With Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe hopes to take on GSK’s Rotarix, the only rotavirus vaccine approved in Japan. And in a crowded DPP-4 field, Mitsubishi looks to double its sales efforts following a deal with Daiichi Sankyo.